Ramucirumab Plus Erlotinib in Metastatic NSCLC With EGFR Ex19del and Ex21L858R Mutations
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-Small Cell Lung Cancer
Clin. Cancer Res 2021 Jul 22;[EPub Ahead of Print], K Nakagawa, E Nadal, EB Garon, M Nishio, T Seto, N Yamamoto, K Park, JY Shih, L Paz-Ares, B Frimodt-Moller, AH Zimmermann, S Wijayawardana, C Visseren-Grul, M ReckFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.